These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26589105)

  • 1. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
    Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ
    Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T; Cochran E; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
    Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.
    Ravussin E; Smith SR; Mitchell JA; Shringarpure R; Shan K; Maier H; Koda JE; Weyer C
    Obesity (Silver Spring); 2009 Sep; 17(9):1736-43. PubMed ID: 19521351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
    Tchang BG; Shukla AP; Aronne LJ
    Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
    Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
    Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G; Akinci B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
    Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
    Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
    Miehle K; Stumvoll M; Fasshauer M; Hierl T
    Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
    Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
    Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
    Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphoma in acquired generalized lipodystrophy.
    Brown RJ; Chan JL; Jaffe ES; Cochran E; DePaoli AM; Gautier JF; Goujard C; Vigouroux C; Gorden P
    Leuk Lymphoma; 2016; 57(1):45-50. PubMed ID: 25864863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
    J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Therapeutic Options in Lipodystrophy.
    Akinci B; Meral R; Oral EA
    Curr Diab Rep; 2018 Oct; 18(12):139. PubMed ID: 30370487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
    J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metreleptin worked in a diabetic woman with a history of hematopoietic stem cell transplantation (HSCT) during infancy: further support for the concept of 'HSCT-associated lipodystrophy'.
    Adachi M; Muroya K; Hanakawa J; Asakura Y
    Endocr J; 2021 Apr; 68(4):399-407. PubMed ID: 33229817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance.
    Moon HS; Matarese G; Brennan AM; Chamberland JP; Liu X; Fiorenza CG; Mylvaganam GH; Abanni L; Carbone F; Williams CJ; De Paoli AM; Schneider BE; Mantzoros CS
    Diabetes; 2011 Jun; 60(6):1647-56. PubMed ID: 21617185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
    Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
    Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides.
    Joseph J; Shamburek RD; Cochran EK; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1676-80. PubMed ID: 24926953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metreleptin: first global approval.
    Chou K; Perry CM
    Drugs; 2013 Jun; 73(9):989-97. PubMed ID: 23740412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.